IMMUSE Therapeutics
- Biotech or pharma, therapeutic R&D
IMMUSE Therapeutics develops innovative immune-based drugs.
- Novel multi-mechanism drugs (inhibitor and degrader) targeting tumor and immune cells simultaneously.
- Next-generation payload antibody conjugates (IM-ADC and DAC).
In particular, we are developing various target-based drugs that induce the control of the tumor microenvironment and the functional recovery of cytotoxic T cells, which are major factors that cause the problems of existing immune checkpoint inhibitors (low reactivity and drug resistance).